Holen Sie sich die Stockscreener-App
1.40
2.10%
-0.03
Schlusskurs vom Vortag:
$1.43
Offen:
$1.43
24-Stunden-Volumen:
4.15M
Relative Volume:
0.86
Marktkapitalisierung:
$375.56M
Einnahmen:
$232.40M
Nettoeinkommen (Verlust:
$-20.51M
KGV:
-18.16
EPS:
-0.0771
Netto-Cashflow:
$60.04M
1W Leistung:
+12.90%
1M Leistung:
+60.38%
6M Leistung:
-7.89%
1J Leistung:
-64.82%
1-Tages-Spanne:
$1.36
$1.4394
1-Wochen-Bereich:
$1.234
$1.46
52-Wochen-Spanne:
$0.8227
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.40 | 375.56M | 232.40M | -20.51M | 60.04M | -0.0771 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
ETFs Investing in Akebia Therapeutics, Inc. Stocks - TradingView
Akebia Therapeutics (AKBA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Akebia Therapeutics (AKBA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
Zacks Research Upgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold - MarketBeat
Akebia Therapeutics (AKBA) Jefferies London Healthcare Conference 2025 Summary - Quartr
AKBAAkebia Therapeutics Inc Options - Finviz
Chief Business Officer Erik Ostrowski Sold A Bunch Of Shares In Akebia Therapeutics - Moomoo
Akebia awards 125,600 stock options to newly hired employees - Stock Titan
AKBA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $6.00 - GuruFocus
Akebia Therapeutics (AKBA) CFO sells 56K shares in tax sell-to-cover - Stock Titan
H.C. Wainwright reiterates Akebia stock rating on trial results By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Akebia TherapeuticsVoice Trial Meets Stopp - Moomoo
U.S. Renal Care and Akebia Therapeutics, Inc. Announce Interim Analysis of VOICE Trial Demonstrates Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo Versus ESA - marketscreener.com
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036 - Yahoo Finance
Akebia (AKBA) VOICE Trial Halted Following Positive Interim Resu - GuruFocus
Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis - marketscreener.com
Akebia: VOICE trial stopped early after vadadustat shows superiority on primary composite endpoint - TradingView
Vafseo shows safer composite outcomes vs ESA in Akebia (AKBA) VOICE trial - Stock Titan
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA - marketscreener.com
Vafseo trial stops early after safety win in dialysis patients - Stock Titan
Form 144 Akebia Therapeutics For: 29 June By Investing.com - Investing.com Australia
Akebia Therapeutics (AKBA) lists 56,019 shares after RSU vesting on 06/28/2026 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akebia Therap - The National Law Review
12 Best Low-Priced Pharma Stocks to Buy Right Now - Insider Monkey
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Price to book forward of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Enterprise value to EBIT forward of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Price to sales forward of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Akebia Therapeutics, Inc. Actuals & Estimates (NASDAQ:AKBA) - TradingView
AKBA Forecast — Price Target — Prediction for 2027 - TradingView
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - Sahm
Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Akebia Therapeutics 8-K Filing: June 2026 Shareholder Vote Results & Company Details - Minichart
Form 4 Akebia Ther For: 22 June By Investing.com - Investing.com Nigeria
Form 8K Akebia Ther For: 22 June By Investing.com - Investing.com Australia
Akebia (NASDAQ: AKBA) director Myles Wolf granted RSUs and options - Stock Titan
Akebia (AKBA) director Cynthia Smith granted RSUs and options for board service - Stock Titan
Akebia Therapeutics (AKBA) grants RSUs and stock options to director Rogers - Stock Titan
[Form 4] Akebia Therapeutics, Inc. Insider Trading Activity - Stock Titan
Akebia Therapeutics (NASDAQ: AKBA) investors back share increase and executive pay - Stock Titan
Akebia Therapeutics (AKBA) director receives RSU and stock option grants - Stock Titan
Akebia Therapeutics (AKBA) awards RSUs and stock options to director Adams - Stock Titan
Akebia Therapeutics, Inc.(NasdaqCM:AKBA) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Q1 2026 Akebia Therapeutics Inc Earnings Call Transcript - GuruFocus
Akebia Therapeutics Inc (AKBA) Institutional Confidence - TradingKey
Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Akebia Therapeutics Inc (AKBA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.42%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):